Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Follow this link:
Anesthesia Masks Market: Rising Prevalence of Chronic Diseases and Neurological Disorders to Drive the Market - BioSpace

Journal Watch: TXA and Neuro OutcomesMore Than Meets the Eye – EMSWorld

Posted on February 2, 2021 by Danzig

Reviewed This Month

Effect of Out-of-Hospital Tranexamic Acid vs. Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.

Authors: Rowell SE, Meier EN, McKnight B, et al.

Published in: JAMA, 2020 Sep 8; 324(10): 96174. Erratum in: JAMA, 2020 Oct 27; 324(16): 1,683.

Over the last decade, the use of tranexamic acid (TXA) for traumatic hemorrhage control has increased. This was due to the results of a clinical trial, published in 2010, that found early administration of TXA was a cost-effective way to reduce the risk of death in bleeding trauma patients.

Further research has shown that TXA is safe for patients with traumatic brain injury (TBI). In this months Journal Watch, we review a randomized, double-blind multicenter trial designed to examine the efficacy and safety of out-of-hospital administration of tranexamic acid compared to placebo in participants with moderate or severe TBI who were not in shock.

The objective of this trial was to determine whether TXA administered by EMS within two hours of injury improved neurologic outcome. Read that objective carefullyit will be important when putting the results of this trial into context.

Neurologic outcome was measured using the Glasgow Outcome Score-Extended (GOSE). The authors chose to dichotomize this scale into favorable (which included moderate disability or good recovery) and poor (which included severe disability, vegetative state, or death) outcomes.

The authors also examined many secondary outcomes, including 28-day mortality, six-month disability, progression of intracranial hemorrhage, incidence of neurosurgical interventions, hospital-free days, ICU-free days, incidence of seizures, and incidence of thrombotic events, to name a few.

The study was conducted in 12 regions across the U.S. and Canada. It included 39 EMS agencies and 20 trauma centers. To be eligible for enrollment in this trial, patients had to be at least 15 years of age, with moderate or severe blunt or penetrating TBI, a GCS score of 3 to 12, at least one reactive pupil, a systolic blood pressure of at least 90 mm Hg, and an IV in place prior to randomization.

Participants were randomized into one of three treatment groups. The first received a 1-gram IV bolus of TXA by EMS followed by a gram of in-hospital TXA infused over eight hours. The next group received a 2-gram TXA bolus by EMS followed by a placebo infusion. The final group received an IV bolus placebo by EMS and a placebo infusion in the hospital. Study kits that appeared identical were shipped to participating EMS agencies for placement on EMS vehicles in random order. Each vehicle only carried one study kit at a time.

The study was conducted between May 2015 and March 2017 under U.S. regulations for exception from informed consent and the Canadian tricouncil policy statement on ethical conduct in research involving humans.

There were 966 patients included in the analysis. Their average age was 42, and almost three-quarters (74%) were male. The average GCS score was 8. The three study groups were similar when comparing demographics and baseline anatomic and physiologic characteristics as well as injury severity. However, the authors note there were fewer penetrating injuries in the bolus-only group.

The median estimated time from injury to EMS administration of the study drug ranged from 40 to 43 minutes. The median time from EMS administration to the start of the in-hospital infusion ranged from 86 to 96 minutes.

The evaluation of the primary study outcome, favorable or poor neurologic function, revealed no statistically significant difference when comparing TXA to placebo (65% vs. 62%, p=0.16). Therefore, the conclusion of this study was that among patients with moderate or severe TBI, out-of-hospital tranexamic acid administration within two hours of injury did not improve six-month neurologic outcome as measured by the GOSE.

However, as we discuss often in this column, we should not let statistical significance alone guide our judgment of importance. There was a 3% difference in favorable neurologic outcome. While that difference may not be statistically significant, could it be clinically meaningful?

Now, rather than simply read the objective and conclusion of this paper, lets dive a little deeper. As mentioned earlier, the authors also examined several secondary outcomes. When evaluating 28-day mortality, the TXA groups showed a 3% improvement (14% vs. 17%). This result was also not statistically significant, with a p-value of 0.26.

There was also an 8% difference in 28-day mortality when comparing the bolus-only group to the placebo group for those patients with intracranial hemorrhage. This difference was statistically significant (p=0.03). The total number of adverse events was also similar between groups.

Why would the authors report such a cut-and-dried conclusion when there seems to be a trend favoring the use of TXA? Well, the authors indicate in their methods section that the study was specifically designed to evaluate neurologic outcomes at six months. This was specified in the original trial registry on ClinicalTrials.gov. The authors had to stick to the primary outcome that was specified prior to the beginning of trial enrollment for the resulting manuscript.

However, the authors are clear that we should carefully interpret their findings. They state in their discussion that despite no statistically significant difference in the primary outcome in either trial, there were important differences and findings from both trials that warrant consideration and future investigation.

In other words, the results seem to be trending in a favorable direction when EMS administers TXA early. So, rather than to simply conclude from these findings that TXA is not effective in the treatment of TBI, an important next step would be to design studies that specifically evaluate outcomes other than the dichotomous GOSE score at six months.

As with all studies there are limitations here. There were some difficulties in obtaining follow-up data six months after the injury. This is not surprising, given that patients were enrolled prior to giving consent. There was also a low percentage of patients with intracranial hemorrhage enrolled in the study. This may have diluted the treatment differences.

This was a very well done study that will lead to further analysis of TXA administration. It is also a great example of how we should avoid letting a p-value alone guide our judgment of importance.

I hope you have an opportunity to read the manuscript yourself. There are many other interesting results that could not fit into this months Journal Watch. And, as always, I hope to review your study in an upcoming edition soon.

Antonio R. Fernandez, PhD, NRP, FAHA, is a research scientist at ESO and an assistant professor in the department of emergency medicine at the University of North CarolinaChapel Hill. He is on the board of advisors of the Prehospital Care Research Forum at UCLA.

Read this article:
Journal Watch: TXA and Neuro OutcomesMore Than Meets the Eye - EMSWorld

Alzheimers Prediction May Be Found in Writing Tests – The New York Times

Posted on February 2, 2021 by Danzig

Is it possible to predict who will develop Alzheimers disease simply by looking at writing patterns years before there are symptoms?

According to a new study by IBM researchers, the answer is yes.

And, they and others say that Alzheimers is just the beginning. People with a wide variety of neurological illnesses have distinctive language patterns that, investigators suspect, may serve as early warning signs of their diseases.

For the Alzheimers study, the researchers looked at a group of 80 men and women in their 80s half had Alzheimers and the others did not. But, seven and a half years earlier, all had been cognitively normal.

The men and women were participants in the Framingham Heart Study, a long-running federal research effort that requires regular physical and cognitive tests. As part of it, they took a writing test before any of them had developed Alzheimers that asks subjects to describe a drawing of a boy standing on an unsteady stool and reaching for a cookie jar on a high shelf while a woman, her back to him, is oblivious to an overflowing sink.

The researchers examined the subjects word usage with an artificial intelligence program that looked for subtle differences in language. It identified one group of subjects who were more repetitive in their word usage at that earlier time when all of them were cognitively normal. These subjects also made errors, such as spelling words wrongly or inappropriately capitalizing them, and they used telegraphic language, meaning language that has a simple grammatical structure and is missing subjects and words like the, is and are.

The members of that group turned out to be the people who developed Alzheimers disease.

The A.I. program predicted, with 75 percent accuracy, who would get Alzheimers disease, according to results published recently in The Lancet journal EClinicalMedicine.

We had no prior assumption that word usage would show anything, said Ajay Royyuru, vice president of health care and life sciences research at IBM Thomas J. Watson Research Center in Yorktown Heights, N.Y., where the A.I. analysis was done.

Alzheimers researchers were intrigued, saying that when there are ways to slow or stop the illness a goal that so far remains elusive it will be important to have simple tests that can warn, early on, that without intervention a person will develop the progressive brain disease.

What is going on here is very clever said Dr. Jason Karlawish, an Alzheimers researcher at the University of Pennsylvania. Given a large volume of spoken or written speech, can you tease out a signal?

For years, researchers have analyzed speech and voice changes in people who have symptoms of neurological diseases Alzheimers, ALS, Parkinsons, frontotemporal dementia, bipolar disease and schizophrenia, among others.

But, said Dr. Michael Weiner, who researches Alzheimers disease at the University of California, San Francisco, the IBM report breaks new ground.

This is the first report I have seen that took people who are completely normal and predicted with some accuracy who would have problems years later, he said.

The hope is to extend the Alzheimers work to find subtle changes in language use by people with no obvious symptoms but who will go on to develop other neurological diseases.

Each neurological disease produces unique changes in speech, which probably occur long before the time of diagnosis, said Dr. Murray Grossman, a professor of neurology at the University of Pennsylvania and the director of the universitys frontotemporal dementia center.

He has been studying speech in patients with a behavioral form of frontotemporal dementia, a disorder caused by progressive loss of nerves in the brains frontal lobes. These patients exhibit apathy and declines in judgment, self control and empathy that have proved difficult to objectively quantify.

Speech is different, Dr. Grossman said, because changes can be measured.

Early in the course of that disease, there are changes in the pace of the patients speech, with pauses distributed seemingly at random. Word usage changes, too patients use fewer abstract words.

These alterations are directly linked to changes in the frontotemporal parts of the brain, Dr. Grossman said. And they appear to be universal, not unique to English.

Dr. Adam Boxer, director of the neurosciences clinical research unit at the University of California, San Francisco, is also studying frontotemporal dementia. His tool is a smartphone app. His subjects are healthy people who have inherited a genetic predisposition to develop the disease. His method is to show subjects a picture and ask them to record a description of what they see.

We want to measure very early changes, five to 10 years before they have symptoms, he said.

The nice thing about smartphones, Dr. Boxer added, is that you can do all kinds of things. Researchers can ask people to talk for a minute about something that happened that day, he said, or to repeat sounds like tatatatata.

Dr. Boxer said he and others were focusing on speech because they wanted tests that were noninvasive and inexpensive.

Dr. Cheryl Corcoran, a psychiatrist at Icahn School of Medicine at Mount Sinai in New York, hopes to use speech changes to predict which adolescents and young adults at high risk for schizophrenia may go on to develop the disease.

Drugs to treat schizophrenia may help those who are going to develop the disease, but the challenge is to identify who the patients will be. A quarter of people with occasional symptoms saw them go away, and about a third never progressed to schizophrenia although their occasional symptoms persisted.

Guillermo Cecchi, an IBM researcher who was also involved in the recent Alzheimers research, studied speech in 34 of Dr. Corcorans patients, looking for flight of ideas, meaning the instances when patients were off track when talking and spinning off ideas in different directions. He also looked for poverty of speech, meaning the use of simple syntactic structures and short sentences.

In addition, Dr. Cecchi and his colleagues studied another small group consisting of 96 patients in Los Angeles 59 of whom had occasional delusions. The rest were healthy people and those with schizophrenia. He asked these subjects to retell a story that they had just heard, and he looked for the same telltale speech patterns.

In both groups, the artificial intelligence program could predict, with 85 percent accuracy, which subjects developed schizophrenia three years later.

Its been a lot of small studies finding the same signals, Dr. Corcoran said. At this point, she said, we are not at the point yet where we can tell people if they are at risk or not.

Dr. Cecchi is encouraged, although he realizes the studies are still in their infancy.

For us, it is a priority to do the science correctly and at scale, he said. We should have many more samples. There are more than 60 million psychiatric interviews in the U.S. each year but none of those interviews are using the tools we have.

Here is the original post:
Alzheimers Prediction May Be Found in Writing Tests - The New York Times

Telerehabilitation: from the virtual world to reality-Medicine in the twenty-first century : Video-assisted treatment in times of COVID-19 – DocWire…

Posted on January 20, 2021 by Danzig

This article was originally published here

Nervenarzt. 2021 Jan 18. doi: 10.1007/s00115-020-01058-w. Online ahead of print.

ABSTRACT

Neurological diseases are the most common cause of disability worldwide. In addition to physical limitations, they often lead to cognitive deficits that make active participation in professional and social life difficult. Due to physical and cognitive deficits, it is often difficult for neurological patients to gain access to specialized knowledge or to receive specialized treatment and is associated with greatly increased effort. Neurological diseases account for 11.6% of global disability-adjusted life years (DALYs, a measure for quantifying disease burden) and 16.5% of deaths, and remain the leading cause of DALYs and the second leading cause of death worldwide. Neurorehabilitation encompasses the goal of reintegrating patients with neurological dysfunctions into everyday life. The ongoing situation in the context of the COVID-19 pandemic poses new challenges for the healthcare system. Social distancing and quarantine have deprived many people with neurological disorders of access to routine medical care. The corona pandemic is a catalyst for the widespread use of telemedicine in the field of neurology and neurorehabilitation. Projects such as the Brunei project of the Nordwest Krankenhaus Frankfurt as well as an MS clinic in Canada show that highly specialized medicine and neurorehabilitation can be delivered to remote areas or in the living room of patients or any doctors office. Telemedical, telerehabilitative and teletherapeutic applications offer the opportunity to supplement and optimize existing care structures and with modern technology to make a new and contemporary interpretation of old-fashioned medical and therapeutic home visits.

PMID:33459797 | DOI:10.1007/s00115-020-01058-w

Read the original:
Telerehabilitation: from the virtual world to reality-Medicine in the twenty-first century : Video-assisted treatment in times of COVID-19 - DocWire...

Loyola Medicine Opens Neurology Clinic for COVID-19 Patients Living with Long-term Neurological and Cognitive Symptoms – Newswise

Posted on January 23, 2021 by Danzig

Newswise MAYWOOD, ILLoyola Medicine is providing multidisciplinary care for patients with long-term neurological, cognitive and other symptoms associated with COVID-19.

"While most patients with COVID-19 have mild-to-moderate symptoms and recover at home, a fraction of severe, typically hospitalized patients (approximately 10%, according to an article in the British Medical Journal) are discharged with lingering, life-altering symptoms," said Jos Biller, MD, professor and chair, department of neurology, Loyola University Medical Center and Loyola University Chicago Stritch School of Medicine. Dr. Biller is leading the Loyola Medicine COVID-19 neurology clinic.

Persistent neurological symptoms in patients following acute COVID-19 may include fatigue; brain fog; loss of smell (anosmia); distorted or loss of taste (dysgeusia); headache; vertigo; sleep disturbances; loss of muscle mass and strength (sarcopenia); and neuromuscular aches, cramps and pain (myalgia).

"These 'long-haul' patients may also have neuropsychiatric symptoms, including anxiety, depression and post-traumatic stress disorder," said Dr. Biller. "As a result of their symptoms, many of these individuals are unable to return to work and suffer economic stressors."

For older patients, COVID-19 may increase the risk for or exacerbate cognitive decline and dementia, said Dr. Biller, who co-authored the study, "Correlations between COVID-19 and burden of dementia" in the September 2020 Journal of the Neurological Sciences. "Many patients with dementia decline significantly after contracting COVID-19."

In addition to Dr. Biller, the Loyola COVID-19 neurology clinic includes neurologists Stasia Rouse, MD and Kathy Kujawa, MD, PhD. The clinic will refer patients to other specialists including psychiatrists, neuropsychologists, pulmonologists, cardiologists, gastroenterologists, nephrologists, and nutritionists as needed.

"The long-term symptoms of COVID-19 may be protracted," said Richard K. Freeman, MD, MBA, regional chief clinical officer, Loyola Medicine. "Loyola Medicine is committed to providing comprehensive, exemplary care to these patients."

For more information, please visit loyolamedicine.org or loyolamedicine.org/coronavirus.

###

About Loyola MedicineLoyola Medicine, a member of Trinity Health, is a nationally ranked academic, quaternary care system based in Chicago's western suburbs. The three-hospital system includes Loyola University Medical Center, Gottlieb Memorial Hospital and MacNeal Hospital, as well as convenient locations offering primary care, specialty care and immediate care services from more than 1,800 physicians throughout Cook, Will and DuPage counties. Loyola is a 547-licensed-bed hospital in Maywood that includes the William G. & Mary A. Ryan Center for Heart & Vascular Medicine, the Cardinal Bernardin Cancer Center, a Level 1 trauma center, Illinois's largest burn center, a certified comprehensive stroke center and a childrens hospital. Loyola also trains the next generation of caregivers through its academic affiliation with Loyola University Chicagos Stritch School of Medicine and Marcella Niehoff School of Nursing. Gottlieb is a 247-licensed-bed community hospital in Melrose Park with the newly renovated Judd A. Weinberg Emergency Department, the Loyola Center for Metabolic Surgery and Bariatric Care and the Loyola Cancer Care & Research facility at the Marjorie G. Weinberg Cancer Center. MacNeal is a 374-licensed-bed teaching hospital in Berwyn with advanced medical, surgical and psychiatric services, acute rehabilitation, an inpatient skilled nursing facility and a 68-bed behavioral health program and community clinics. Loyola Medical Group, a team of primary and specialty care physicians, offers care at over 15 Chicago-area locations. For more information, visit loyolamedicine.org. You can also follow Loyola Medicine on LinkedIn, Facebook or Twitter.

About Trinity Health Trinity Health is one of the largest multi-institutional Catholic health care delivery systems in the nation, serving diverse communities that include more than 30 million people across 22 states. Trinity Health includes 92 hospitals, as well as100continuing care locations that include PACE programs, senior living facilities, and home care and hospice services. Its continuing care programs provide nearly 2.5 million visits annually. Based in Livonia, Mich., and with annual operating revenues of$18.8billion and assets of$30.5 billion, the organization returns$1.3billion to its communities annually in the form of charity care and other community benefit programs. Trinity Health employs about123,000colleagues, including6,800employed physicians and clinicians. Committed to those who are poor and underserved in its communities, Trinity Health is known for its focus on the country's aging population. As a single, unified ministry, the organization is the innovator of Senior Emergency Departments, the largest not-for-profit provider of home health care services ranked by number of visits in the nation, as well as the nations leading provider of PACE (Program of All Inclusive Care for the Elderly) based on the number of available programs. For more information, visit trinity-health.org. You can also follow Trinity Health on LinkedIn, Facebook or Twitter.

More here:
Loyola Medicine Opens Neurology Clinic for COVID-19 Patients Living with Long-term Neurological and Cognitive Symptoms - Newswise

Soterix Medical study to address post-COVID neurological and psychiatric symptoms using at-home neuromodulation and monitoring – PRNewswire

Posted on February 2, 2021 by Danzig

NEW YORK, Jan. 26, 2021 /PRNewswire/ --Soterix Medical Inc. (SMI), the global leader in non-invasive stimulation and synergistic brain imaging technologies, announces a new clinical trial of home-based auricular Vagus Nerve Stimulation (taVNS) for individuals who experience post-COVID neuropsychiatric symptoms, like fatigue, headache, or anxiety. The trial involves an innovative, first-of-its kind home-based neuromodulation solution that combines Soterix Medical's unique wearable taVNS platform, with ElectraRx portal for remote stimulation control, and home-based vital sign monitoring.

Emerging studies show COVID can affect patients during two distinct phases of the disease process: the acute stage, characterized by fever, heart or lung problems, and the post-COVID phase, in which neuropsychiatric symptoms, like fatigue, anxiety and depression, can occur.

Researchers have used the term "neuroCOVID" to describe when the second phase is characterized by one or a combination of neuropsychiatric symptoms like vertigo, loss of smell, headaches, fatigue and irritability as well as anxiety and depression. Some studies estimate one in five COVID patients will develop these long-term symptoms.

The study is supported in part by the National Institutes of Health-funded Delaware Clinical and Translational Research Program to address neuroCOVID symptoms in patients. The trial is designed around a unique technology suite that combines precise vagus nerve stimulation with real-time remote-control as well as remote physiological sensing by the clinical team. The trial is based on the established anti-inflammatory response to vagus nerve stimulation.

Mr. Kamran Nazim, Chief Product Manager of Soterix Medical adds, "This study will leverage our unparalleled expertise in developing noninvasive technologies to stimulate the vagus nerve. Soterix Medical has over a decade of experience designing and deploying the more reliable, targeted, and intelligent non-invasive brain stimulation devices. Our proprietary remote-controlled taVNS system is uniquely optimized for this novel indication."

Ms. Claudia Giselle, Soterix Medical's VP Regulatory Affairs, adds "In addition to Soterix Medical's unique wearable vagus nerve stimulation platform, this trial integrates technology for telemedicine support including video and real-time home-based blood pressure, pulse and oxygen saturation levels. The sophistication of this integrated system is a testament to our commitment to provide the most advanced stimulation and integrated monitoring technologies, for the most important medical indications of our time."

CAUTION: Soterix Medical taVNS platform is limited by Federal (or United States) law to investigational use only.

Media Contact: Mariana Shuster Tel: +1-888-990-8327 Email: [emailprotected]

SOURCE Soterix Medical Inc.

Read this article:
Soterix Medical study to address post-COVID neurological and psychiatric symptoms using at-home neuromodulation and monitoring - PRNewswire

Film review: the immoderate adventures of Oliver Sacks – The Conversation AU

Posted on December 4, 2020 by Danzig

Review: Oliver Sacks: His Own Life, directed by Ric Burns

Apropos of nothing but a bowl of jello placed before him, a stifled laugh escapes from Oliver Sacks, the famed neurologist, writer and public intellectual.

What are you thinking about? asks a voice offscreen.

Sacks demurs at first or perhaps feigns reluctance then relents.

Until a few years ago, I would wake up at night with an erection. Nothing to do with sexual excitement But it was at times irritatingly persistent. So, I would sometimes cool my turgid penis in orange jello.

Such vignettes from Oliver Sacks: His Own Life reveal the usually shy, but often cheeky and sometimes shockingly honest character of the late Sacks.

Shortly after receiving a fatal diagnosis in January, 2015, Sacks invited documentarian Ric Burns and crew for a series of interviews in his New York City apartment. Sacks second memoir, On the Move, would be published in April. He passed away just a few months later.

Read more: 'I want to stare death in the eye': why dying inspires so many writers and artists

The film is structured around Sacks reading brief passages from his memoir, accompanied by archival footage of the avuncular physician in action. Also interspersed are pithy recollections from fellow neurologists, writers, editors, patients, family and friends.

Rather than retreading previous thoughts on Sacks style of romantic science, its worth considering what the documentary offers that existing memoirs, biographies and other accounts do not.

Firstly, for those unfamiliar with Sacks, the film provides the most efficient but palatable jello anecdotes aside summary of his life, work and character.

Moreover, it reconciles how Sacks seemingly wild contradictions would (eventually) become complements. A recurring theme is that Sacks was immoderate in all directions, living a life that whiplashed between extremes of hedonism and self-discipline.

Sacks possessed a curious mix of extraordinary erudition, voracious appetite and self-destructive tendencies. This was leavened by seemingly boundless empathy for the neurologically marginalised, for whom he so poetically advocated.

Read more: How Oliver Sacks brought readers into his patients' inner worlds

By all accounts, including those of his partner Bill Hayes, Sacks could be painfully shy, yet effusively gregarious when taken by sudden, ebullient outbursts of boyish enthusiasm.

As a young man wracked with anguish regarding his sexuality and unrequited affections, Sacks once resolved never to live with anyone again. So began 35 years of celibacy, when Sacks took on an almost monastic dedication to his work.

However, Sacks first turned to drugs as a sort of compensation, acquiring a fierce amphetamine habit that proved inspiring and corrosive.

Yet Sacks also sought mastery over his body, becoming an exceptional weightlifter.

Oscillating between roles as Dr Squat the athlete, Wolf the speedfreak biker, and Ollie the kindly but unconventional neurologist, Sacks often remained ill at ease.

Perhaps only in his very late years, through his relationship with Hayes including a very late discovery of French kissing on his 76th birthday did Sacks find comfort.

Read more: Oliver Sacks, the brain and God

Born into a typical, Orthodox Jewish, middle-class family during the 1930s, Sacks father, Sam, was an affable GP, while his mother, Elsie, was a highly regarded gynaecologist, and among the first women surgeons in England.

Sacks reports an an uneasy closeness with his mother.

I think she wanted me to be like her. Sometimes, especially when I was very young she would bring a fetus home, and suggest I dissect it. That was not so easy for a child of ten or eleven.

Later, upon discovering Oliver was gay, his mother declared him an abomination. Though they remained close, Sacks lamented that her words haunted me for much of my life.

Sacks and his brother Michael were sent to boarding school during the Battle of Britain. Soon after this harrowing experience Michael was diagnosed with schizophrenia. Sacks became both terrified of him, terrified for him and retreated into a fondness for chemistry.

Only after many years could Sacks work his way back towards contemplating the minds of others.

Famously clumsy, Sacks initially aspired to be a lab scientist, but after numerous calamities was instructed to Get out, see patients, youll do less harm.

His vocational approach as a neurologist often more resembled a naturalist than a clinician. For Sacks, observation and play trumped diagnosis and prescription.

Indeed, in a biography by Lawrence Weschler, Sacks notes his main neurological tool is the ball You can learn much from how patients play.

Read more: Celebrating Oliver Sacks' romantic science and a life now ending

To compress any life let alone one as Forrest Gumpian as Sacks into a two hour film is something of a fools errand.

Hence, narrative compromises were always likely. Sacks travels in Canada, where he briefly tried joining the Royal Canadian Air Force, are skipped entirely.

Similarly, perhaps in deference to a subject granting privileged access during his last days, the documentary veers ever so slightly into hagiography, framing Sacks as a unifying figure between the clinical and experimental neurosciences.

Still, Sacks influence is undeniably staggering, and His Own Life provides a compelling account of the empathetic labours needed for otherwise lost souls to be storied into the world.

Oliver Sacks: His Own Life is in cinemas now.

Read the original:
Film review: the immoderate adventures of Oliver Sacks - The Conversation AU

Interventional Neurology Devices Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 – NeighborWebSJ

Posted on January 20, 2021 by Danzig

Fort Collins, Colorado: Reports Globe has published the latest study on Interventional Neurology Devices Market Report Analysis by Size with Future Outlook, Key Players SWOT Analysis and Forecast to 2026. It uses exploratory techniques such as qualitative and quantitative analysis to identify and present data on the target market. Successful sales strategies have been mentioned that will help you do business in record time and multiply customers.

This report is presented clearly and concisely to help you better understand the structure and dynamics of the market. The trends and recent developments in the Interventional Neurology Devices market were analyzed. The opportunities that lead to the growth of the market were analyzed and presented. Focusing on the global market, the report provides answers to the key questions stakeholders are facing today around the world. Information on market size raises the problem of increasing competitiveness and hampering market-leading sectors and market growth.

Get Exclusive Sample of Report on Interventional Neurology Devices market is available @ https://reportsglobe.com/download-sample/?rid=126683

Some of the Important and Key Players of the Global Interventional Neurology Devices Market:

Interventional Neurology Devices market research report provides detailed information on the following aspects: Industry Size, Market Share, Growth, Segmentation, Manufacturers and Advancement, Key Trends, Market Drivers, Challenges, Standardization, Deployment Models, Opportunities, Strategies, Future Roadmaps and Annual Forecasts to 2027, etc. The report will help you also in understanding the dynamic structure of the Interventional Neurology Devices market by identifying and analyzing market segments. The Global Interventional Neurology Devices 2021 Industry Research Report has given the expected compound annual growth rate (CAGR) as a% of value for a given period of time and clearly helps the user make their decision based on the futuristic chart of the key players on the global Interventional Neurology Devices market. The report introduces some of the major players in the global Interventional Neurology Devices market and offers insightful information about the Interventional Neurology Devices industry such as Business Overview, Interventional Neurology Devices Market Product Segmentation, Revenue Segmentation, and the Latest Information. Developments.

Additionally, the Interventional Neurology Devices market report includes a comprehensive strategic review as well as summarized studies of the growth, key factors, and market opportunity by which to evaluate the Interventional Neurology Devices market and other important market related details on Interventional Neurology Devices. The investigation of the research report also helps uncover accurate industry statistics depicting the ultimate model of the global Interventional Neurology Devices market, including various types, applications, market growth structures, and opportunities. In addition, the study of the market research report provides an investigation and analysis of the past and current performance of the regional market that includes regions by department and subdivision. This regional analysis studies various key market parameters such as Interventional Neurology Devices market growth rate in each region, production volume and capacity, market demand and supply, and return on investment (RoI).

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=126683

Some of the key questions answered in the report include-

1. What is the overall structure of the market?2. What was the historical value and what is the forecasted value of the market?3. What are the key product level trends in the market?4. What are the market level trends in the market?5. Which of the market players are leading and what are their key differential strategies to retain their stronghold?6. Which are the most lucrative regions in the market space?

Browse the complete report @ https://reportsglobe.com/product/global-interventional-neurology-devices-market-insight/

Global Interventional Neurology Devices market is segmented based by type, application and region.

Interventional Neurology Devices Market Segmentation, By Type

Interventional Neurology Devices Market Segmentation, By Application

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Global Interventional Neurology Devicesmarket Key Report Highlights:

This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary, and market segments The report also includes sections on the competitive spectrum, highlighting major players, with a detailed assessment of supply chain management, competition dynamics, and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis, and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in the global Interventional Neurology Devices market.A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post-COVID-19 market environment.

Major Points from Table of Content:

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Interventional Neurology Devices Market Overview5. Interventional Neurology Devices Supply Chain Analysis6. Interventional Neurology Devices Pricing Analysis7. Global Interventional Neurology Devices Market Analysis and Forecast by Type8. Global Interventional Neurology Devices Market Analysis and Forecast by Application9. Global Interventional Neurology Devices Market Analysis and Forecast by Sales Channel10. Global Interventional Neurology Devices Market Analysis and Forecast by Region11. North America Interventional Neurology Devices Market Analysis and Forecast12. Latin America Interventional Neurology Devices Market Analysis and Forecast13. Europe Interventional Neurology Devices Market Analysis and Forecast14. Asia Pacific Interventional Neurology Devices Market Analysis and Forecast15. Middle East & Africa Interventional Neurology Devices Market Analysis and Forecast16. Competition Landscape

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://reportsglobe.com/need-customization/?rid=126683

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

Valley neurologist will work at Super Bowl for the third time – 12news.com KPNX

Posted on February 6, 2021 by Danzig

One of Arizonas premier brain injury doctors will travel to Tampa Bay to bring his expertise to the sports worlds biggest stage.

TAMPA, Fla. Dr. Javier Cardenas has worked on the sidelines for three Super Bowls. Hes the director of Concussion and Brain Injury at the Barrow Neurological Institute.

During Sundays game between the Tampa Bay Buccaneers and the Kansas City Chiefs in Florida, Cardenas will serve as a backup concussion doctor.

Cardenas said players are generally cooperative when undergoing concussion protocols, even if it means being pulled from the game.

There is almost never push and pull, Cardenas said. Of course, they want to play, but this process is a collaboration between the NFL and players association.

Concussion protocols were established during negotiations between the players union and the NFL. Over the years, Cardenas says the culture has changed and players understand the dangers of concussions.

When Kansas City Chiefs star quarterback Patrick Mahomes showed signs of concussion in a playoff game three weeks ago, he dutifully exited the field. Cardenas says thats a sign of where the NFL is at today.

Cardenas reminds young athletes that players have even been pulled from the Super Bowl if they show signs of brain injury.

Whether they (high school athletes) say we have a big rivalry game coming up or the state championships, what I remind them is that even in the biggest game of the world, we are removing athletes from play, Cardenas said.

Follow this link:
Valley neurologist will work at Super Bowl for the third time - 12news.com KPNX

Cell discovery may be key to treating currently incurable neurological diseases – Eyewitness News (WEHT/WTVW)

Posted on November 30, 2020 by Danzig

Posted: Nov 29, 2020 / 01:55 PM CST / Updated: Nov 29, 2020 / 04:30 PM CST

Dr. Benjamin Segal (left) and Dr. Andrew Sas examine the properties of a newly-discovered cell in a lab at The Ohio State University Wexner Medical Center. This immune cell has the potential to treat neurological conditions long believed to be incurable, including multiple sclerosis, ALS and spinal cord injuries.

COLUMBUS, Ohio (WEHT) For the millions of people suffering from a neurological condition, the devastating effects have long been believed to be irreversible. A discovery at The Ohio State University Wexner Medical Center provides new hope for recovery from degenerative neurological diseases such as ALS and multiple sclerosis as well as from damage caused by traumatic brain and spine injuries and stroke.

The cell discovered by these researchers is a type of white blood cell that not only prevents nerve cell death, but partially reverses nerve fiber damage and promotes nervous system repair. Study findings are published in the journal Nature Immunology.

This immune cell subset secretes growth factors that enhance the survival of nerve cells following traumatic injury to the central nervous system. It stimulates severed nerve fibers to regrow in the central nervous system, which is really unprecedented, said Dr. Benjamin Segal, professor and chair of the Department of Neurology at The Ohio State College of Medicine and co-director of the Ohio State Wexner Medical Centers Neurological Institute.

The next step is to harness this cell and grow it in a lab to enhance its healing effects. Researchers hope these cells can then be injected into patients to improve function and mobility and slow or stop degenerative decline.

For the latest breaking news and stories from across theTri-State, follow Eyewitness News onFacebookandTwitter.

(This story was originally published on November 29, 2020)

LATEST LOCAL NEWS:

See the article here:
Cell discovery may be key to treating currently incurable neurological diseases - Eyewitness News (WEHT/WTVW)

Interventional Neurology Device Market 2021 Market Exclusive insight on Transformation 2026 Murphy’s Hockey Law – Murphy’s Hockey Law

Posted on January 23, 2021 by Danzig

Interventional Neurology Device Market Report offers a comprehensive analysis of the Interventional Neurology Device industry, standing on the readers perspective, delivering detailed market data, and penetrating insights. No matter the client is an industry insider, potential entrant, or investor, the report will provide useful data and information.

The report demonstrates detailed coverage of theInterventional Neurology Device industry and main market trends. The market research includes historical and forecast data, like demand, application details, price trends, and company shares of the leading Interventional Neurology Device by geography, especially focuses on the key regions like United States, European Union, China, and other regions. This report studies and analyzes the in-depth impact of Coronavirus COVID-19 on the Interventional Neurology Device industry.

In addition, the report provides insight into the main drivers of market demand and strategies of suppliers. Key players are profiled, and their market shares in the global Interventional Neurology Device market are discussed. And this report covers the historical situation, present status, and the future prospects of the global Interventional Neurology Device market.

Request for a sample copy of the report to get extensive insights into the Interventional Neurology Device market at https://www.in4research.com/sample-request/57120

Interventional Neurology Device Market: Players Segment Analysis (Company and Product introduction, Interventional Neurology Device Sales Volume, Revenue, Price, and Gross Margin):

Interventional Neurology Device Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share, and Trend 2016-2026):

Interventional Neurology Device Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis):

Interventional Neurology Device Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue, and Growth Rate 2016-2026):

For more Customization, Connect with us at https://www.in4research.com/customization/57120

Interventional Neurology Device Market Research Objectives:

Any Questions/Queries or need help? Speak with our analyst https://www.in4research.com/speak-to-analyst/57120

Interventional Neurology Device Market Report Includes:

Significance of the report which makes it worth buying:

Buy Full Report athttps://www.in4research.com/buy-now/57120

For More Details Contact Us:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

https://murphyshockeylaw.net/

Excerpt from:
Interventional Neurology Device Market 2021 Market Exclusive insight on Transformation 2026 Murphy's Hockey Law - Murphy's Hockey Law

Beyond COVID-19, where will biopharma focus in 2021? – FierceBiotech

Posted on January 23, 2021 by Danzig

Fighting the pandemic will remain a top priority in 2021, not least for the biopharma companies working on the next generation of therapeutics and vaccines against COVID-19. But just because were in a pandemic doesnt mean all other diseases have stopped plaguing humanity. We asked executives which areas might see a resurgence this year, and neurology emerged as a popular horse to bet on.

Part of that interest could be down to Biogens once-failed Alzheimers disease candidate, aducanumab, which is slated for an FDA decision by March 7.

I think neurology will continue to be a big focus, at least in the first half of the year, while aducanumab is out there and all eyes are on the PDUFA, said Shehnaaz Suliman, M.D., president and chief operating officer of Alector, which is working on immuno-neurology approaches to neurodegenerative disease. There was a recent spate of high-priority deals done in the neuro spaceit signals appetite in Big Pharma and Big Biotech to do big value-creating deals.

RELATED: JPM: Alector, Annexon, Athira on what an aducanumab approval could mean for Alzheimer's R&D

Multiple executives agreed that aducanumab would not be a best-in-class drug but that its approval would give the whole field a boost, encouraging interest and investment in neurodegenerative disease R&D. Recent data for a similar drug, Eli Lillys donanemab, also offered hope.

I think its important to continue to go after neurology," said Doug Love, president and CEO of Annexon Biosciences. We are an aging population, and, of course, patients are going to have neurodegenerative disorders We need to think smart and branch out beyond Alzheimers. There are lots of neurodegenerative diseases. There are lots of kinds of dementia we can target.

Its a good time to pursue these indications, Love said, adding, As the field advances with various biomarkers, we will understand earlier in the disease process if drugs are working.

Another reason traditionally big indications like neurology and cardiology are getting more interest is the availability of genetic sequencing and the ability to slice those disease areas up into more manageable segments. It provides a regulatory path for companies working in those areas that previously did not exist, said Rahul Ballal, Ph.D., CEO of Imara, a company working on treatments for sickle cell disease and other blood disorders.

RELATED: JPM: Biogen bullish on Alzheimer's drug approval, sees Lilly data as positive despite AdComm rejection

For a long time, people have run away from those spaces for all the reasons you know: low probability of technical success, large, heterogeneous patient populations, Ballal said. And I think what biotech is doing thats really exciting within the neurodegenerative space and within cardiovascular disease is they are applying a rare disease approach to those diseases by finding patients within the very large swaths.

Whichever areas receive the most interest in 2021, the entire industry should make sure that treatments reach every patient who needs them, said Nessan Bermingham, CEO of Triplet Therapeutics.

We look at whats happening with the (COVID-19) vaccine and whats happening with the rollout of care for individuals who have gotten COVID-19, and the disparities are very clear, Bermingham said. In the U.S. and from a global standpoint, were only going to see those be further emphasized. This is something, as a biotech industry, we need to be very conscious of.

Biopharma companies should think about pricing, distribution and access not just of cutting-edge immuno-oncology meds and gene therapies but also of things like basic care, real-time feedback from doctors, diagnostics and imaging.

As we think about the disparities we face, weve not changed that, and arguably with new therapies coming out, weve actually made those disparities worse, Bermingham added. I think as an industry, we need to go back to the concept of healthcare democracy: that everyone has the right to healthcare.

Go here to see the original:
Beyond COVID-19, where will biopharma focus in 2021? - FierceBiotech

Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs – PRNewswire

Posted on February 4, 2021 by Danzig

CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ --Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming to innovate in the complex field of neurological diseases. The incubator space is located at the Eisai Center for Genetics Guided Dementia Discovery (G2D2) facility and will become part of BioLabs' national biotechnology network.

"We are excited to announce this collaboration with BioLabs," said Nadeem Sarwar, Ph.D. and President of G2D2. "This specialized incubator will be the first of its kind. With BioLabs' focus on building ecosystems that foster rapid innovation combined with G2D2's state-of-the-art technology to support neurological research, we believe the creation of the Eisai Innovation Center BioLabs will fuel new scientific discoveries and insights. With more than 50 million people globally living with dementia1, there has never been a greater need for the discovery of novel approaches to prevention and treatment."

Housed in the G2D2 facility, the Eisai Innovation Center BioLabs aims to host five to seven neurology-focused start-ups and provide the infrastructure and support to help build their biotech companies. The facility was custom-designed for discovery research, including capabilities for in-vitro biology, molecular and cellular biology including BioSafety Level 2 tissue culture, microscopy, chemical and structural biology and screening. Companies hosted at this incubator will have the opportunity to access the BioLabs network, and interact with the Eisai network, including G2D2 and Eisai's investment arm, Eisai Innovation Inc.

"Launching this incubator space in partnership with BioLabs is an important milestone in our relentless pursuit of a cure for neurological diseases, including Alzheimer's disease, and the fulfillment of our human health care mission. In this new specialized model, we want to advance beyond offering only co-working space," said Vanessa Almendro, MBA, Ph.D. and Head of Strategy and External Innovation at G2D2. "By providing scientific support and enabling potential collaborative opportunities, the Eisai Innovation Center BioLabs is pioneering in providing unique, broad and tailored support to the most prominent biotech companies developing transformative therapies, devices and digital solutions for patients suffering from neurological disorders."

The integration with BioLabs, a national, membership-based network of shared lab and office facilities located in key biotech innovation clusters, empowers companies to rapidly launch their operations in a full-equipped, ready-to-use facility, while collaborating with other innovators in the field.

"The custom-designed space at G2D2 is an ideal home for the Eisai Innovation Center BioLabs. The open-lab layout naturally fosters integration between entrepreneurs, all focused on understanding and advancing the field of neurological diseases. Interacting with a community of peers, specifically within a specialized area of research, sparks collaboration and can significantly fast track a start-up's evolution," said Adam Milne, Chief Operating Officer at BioLabs.

A joint selection committee with members of Eisai Inc., Eisai Innovation Inc. and BioLabs representatives will select the companies to be invited. The selection committee will prioritize start-ups focused on neurology, aligned with Eisai's human health care mission and showing strong potential to develop curative therapeutics. To learn more about the incubator, visit our website.

About Eisai Inc. At Eisai Inc., human health care (hhc)is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at http://www.eisai.com/US and follow us on Twitter and LinkedIn.

About Eisai Innovation, Inc.Eisai Innovation, Inc.(EII) is a subsidiary of Eisai Inc. It is a strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies. EII contributes toour human health care (hhc)mission by prioritizing disease prevention, prediction and treatment through global investments and research collaboration.

About G2D2Eisai Center for Genetics Guided DementiaDiscovery (G2D2) is the first research center focused on immunodementia. As part of Eisai's Neurology Business Group, G2D2 draws upon Eisai's cutting-edge strengths in human genetics, data sciences and precision chemistry to accelerate discovery of breakthrough immunodementia precision therapeutics.

G2D2 is located in the Alewife Research Center in the Alewife area, in the north-west part of Cambridge, which is one of the world's leading biotechnology clusters where private research organizations in addition to academic institutions such as Harvard University, the Massachusetts Institute of Technology and Tufts University are concentrated. Leveraging the benefits of the location, a research space that can be used by external organizations will be set up at G2D2 to enhance collaboration with outstanding researchers and open innovation initiatives to promote immunodementia drug discovery.

About BioLabsBioLabsis a membership-based network of shared lab facilities located in the nation's key biotech innovation clusters, designed exclusively for high-potential, early-stage life science companies. It offers co-working environments that pair premium, fully equipped and supported lab and space with unparalleled access to capital and industry partners. Find out more athttps://www.biolabs.io/

References

Contact:

Eisai Inc. Libby Holman201-753-1945 [emailprotected]

SOURCE Eisai Inc.

http://www.eisai.com

View post:
Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs - PRNewswire

Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations – Business Wire

Posted on December 4, 2020 by Danzig

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the companys Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities.

I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts, said Carmine Stengone, President & CEO of Pipeline Therapeutics. Julies extensive experience in managing drug candidates through the clinic, across a variety of therapeutic areas, will benefit us greatly as we move our neuroregenerative candidates through clinical studies and assemble the data packages needed for eventual NDA submissions.

I am delighted to be joining the Pipeline team, just as the companys lead program, PIPE-505 for sensorineural hearing loss, is progressing through a proof-of-concept Phase 1/2a study, and as PIPE-307 enters the clinic, both candidates with great potential to help patients with unmet medical needs, said Ms. Iwashita. I believe Pipeline Therapeutics is well-positioned to transform the current treatment of neurological disorders, based on its exciting and proprietary technology covering synaptogenesis, remyelination and axonal repair.

Julie most recently served as Vice President of Clinical Operations for Cirius Therapeutics, a clinical-stage pharmaceutical company focused on the development of treatments for liver and metabolic diseases. Previously she served as Executive Director, Clinical Operations at Kodiak Sciences Inc., (NASDAQ: KOD). Prior to Kodiak, Julie served as Executive Director of Clinical Development at Laguna Pharmaceuticals and before that at Sorbent Therapeutics. Prior to Sorbent, Julie was Senior Director of Clinical Development at MAP Pharmaceuticals, Proteolix, Inc. and Affymax, Inc. (OTCMKTS: AFFY). Julie has served as a consultant for multiple private and public biotech companies exploring neurological disorders including age-related macular degeneration, spinal cord injury, and migraine headaches. She has also managed clinical programs at Genitope, Aviron, Amgen and Syntex in therapeutic areas including renal, cardiovascular, and oncology.

Julie holds a bachelors degree in human biology from Stanford University.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit http://www.pipelinetherapeutics.com.

Read the original here:
Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations - Business Wire

UB researcher co-chairs international panel that expanded guidance for caring for patients with myasthenia gravis – UB News Center

Posted on December 4, 2020 by Danzig

BUFFALO, N.Y. A University at Buffalo researcher recently co-led a panel of 16 international experts on myasthenia gravis (MG) to revise and expand recommendations for managing the disease. Their paper was published in the journal Neurology on Nov. 3.

Gil I. Wolfe, MD, Irvin and Rosemary Smith Chair of the Department of Neurology in the Jacobs School of Medicine and Biomedical Sciences at UB and president of UBMD Neurology, served as co-chair of the panel. He also co-chaired the same panel in 2016, when the guidelines were originally developed.

The new guidance for clinicians is based on the latest evidence in the literature. This updated formal consensus guidance provides recommendations to clinicians caring for MG patients worldwide.

Some wealthy countries have established their own guidelines, but most of the world cannot do that, Wolfe said.The international panel, using the UCLA/RAND Appropriateness Methodology to achieve a formal consensus, hopes to fill that void, providing a treatment/management framework for health care providers, industry, insurers and the patient community.

MG is a rare autoimmune disease affecting neuromuscular function. As many as 60,000 Americans have been diagnosed with MG, and its incidence is increasing as a result of improved diagnostic techniques and an aging population. Symptoms of MG include droopy eyelids; blurred or double vision; difficulty speaking, swallowing and breathing; and muscle weakness.

One of the main revisions to the recommendations encourages thymectomy (surgical removal of the thymus gland) in the largest subpopulation of MG patients. This change is based on a clinical trial for which Wolfe was the principal investigator. Results of that trial were published in the New England Journal of Medicine in 2016 and in The Lancet Neurology in 2019.

A new recommendation was also developed for the use of eculizimab, a complement inhibitor that is the first FDA-approved immunotherapy for MG.

The panel also revised recommendations for the use of rituximab and methotrexate, as well as for early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment.

In addition, there are some warnings in the recommendations pertaining to worsening MG clinical status in regard to certain therapies that have been touted for use in COVID-19, Wolfe said.

A list of panel participantsand their institutions is available in thepaper.

See more here:
UB researcher co-chairs international panel that expanded guidance for caring for patients with myasthenia gravis - UB News Center

Global Interventional Neurology Device Market 2020 Growth By Manufacturers, Type And Application, Forecast To 2026 : Medtronic, Medikit Co., Ltd.,…

Posted on December 1, 2020 by Danzig

A newly added research report by Orbis Pharma Reports evaluating various developments and eventful milestones in global Interventional Neurology Device market suggests that the aforementioned market is an emerging one with ample scope for refurbishments and developments. Inclined to render optimum investment guidance for accurate pandemic management, this versatile research report also sheds ample light on COVID-19 pandemic management and evolution guide to emerge successfully from limitations that have stunned growth progression substantially. Thorough research offerings compiled by Orbis Phrama Reports suggest that owing to favorable market conditions and rampant market opportunities in the previous decades, several market participants have directed investment aggressively towards novelties.This in-depth research report initiated by Orbis Pharma Reports equips readers with ample market advantages, allowing manufacturers to spot crucial cues pertaining to market rivalry, competition intensity. The report also allows readers to gauge into technological innovations to enable diffusion of technological advances into market investments, thus deriving maximum benefits.

Get sample copy of Interventional Neurology Device Market report @ https://www.orbispharmareports.com/sample-request/74247

Segment Identification:

This detailed market synopsis by Orbis Pharma Reports depicting current market scenario highlights crucial details on SWOT analysis, PESTEL analysis and Porters Five Forces analytical reviews to understand market developments in real time. Market Relevant information have been professed with great detail in the report to encourage high investment returns by leading players in global Interventional Neurology Device market. The report carries out a deep analytical study to identify and understand the potential of core factors that stimulate high end growth.This high-end research report assessing the market scenario lends ample insights on various market facets concerning market segments. The segmentation concerning global Interventional Neurology Device market identifies product and service categories as vital segments. Additional segments also include applications and geographical expanse as prominent market segments harnessing revenue diversifications which also have been evaluated with great detail in this Orbis Pharma Reports presentation. This segment intensive information presented in the report influence competitive edge amongst report readers and inquisitive market participants.

Major Company Profiles operating in the Interventional Neurology Device Market:

MedtronicMedikit Co., Ltd.Penumbra, Inc.Johnson and JohnsonMicroport Scientific CorporationTerumo CorporationW.L. Gore & AssociatesMerit Medical Systems, IncStryker

Read complete report along with TOC @ https://www.orbispharmareports.com/global-interventional-neurology-device-market-insight-and-forecast-to-2026/

Regional Developments: an Overview:

In the following report sections, research analysts at Orbis Pharma Reports reveal an overview of various geographical developments that play crucial role in growth enablement. Several prominent growth beds available across varied regions have been identified in detail to understand vendor preferences and investment discretion besides tapping on novel growth opportunities prevalent across different regions.Across MEA, South Africa and GCC countries demonstrate promising growth potential. European nations such as Germany, Italy, France and Scandinavian countries offer immense growth potential. Across APAC, countries such as Australia, Southeast Asian countries, India, Japan, and China are likely to remain afloat. Further in regional segmentation, Orbia Pharma Reports identifies Canada and the US to remain most favorable growth beds.

By the product type, the market is primarily split into

Embolization & coilingNeurothrombectomy Devices

By the application, this report covers the following segments

Treatment of Cerebral AneurysmsTreatment of Cerebral VasospasmVertebroplasty

The following is a brief of some of the most insightful report offerings, vital to deploy appropriate business decisions in global Interventional Neurology Device market to influence market stability and revenue generation.1.Orbis Pharma Reports sketches a thorough analytical demonstration of the global Interventional Neurology Device market, inclusive of versatile details on current market trends and futuristic growth estimations2.The report lends a versatile perspective of market growth influencers that allow in comprehending key market trends harnessing lucrative foothold amidst staggering competition3.The report by Orbis Pharma Reports also ensures a systematic DROT assessment with elaborate references of market manacles and growth initiators besides hovering over ample market opportunities and novel avenues.4.Additional details on overall remunerative value and market competencies have also been minutely identified to ensure stability and sustenance in this unique market research documentation by Orbis Pharma Reports .5.Advanced research and analytical practices such as PORTERs Five Forces analytical methods have been followed to understand trade competencies of buyer and supplier terrains.

For Any Query on the Interventional Neurology Device Market: https://www.orbispharmareports.com/enquiry-before-buying/74247

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Coronavirus may enter the brain through the nose – the neurological symptoms to look for – Express

Posted on December 1, 2020 by Danzig

The research describes how SARS-CoV-2 not only invades the respiratory tract but also impacts the central nervous system (CNS), resulting in neurological symptoms such as loss of smell, taste, headache, fatigue and nausea.

It does this by infecting the human brain via nasal mucus, the study has found.

The finding is the first of such to demonstrate how the coronavirus can enter the brain's neurons via the mucosal pathway.

To confirm their hypothesis, Scientists in Germany performed autopsies on 33 patients who died of COVID-19.

READ MORE:Coronavirus can disrupt chemesthesis - and the effects may show up when eating spicy food

The study does not establish how the virus advances to the brain from this point, however.

"Our data suggest that the virus moves from nerve cell to nerve cell in order to reach the brain," explains Dr Helena Radbruch, one of the academics who worked on the study.

"It is likely, however, that the virus is also transported via the blood vessels, as evidence of the virus was also found in the walls of blood vessels in the brain."

The study also detected the presence of immune cells in the cerebral fluid, which were activated following infection.

Professor Heppner said: "In our eyes, the presence of the virus in nerve cells of the olfactory mucosa provides good explanation for the neurologic symptoms found in patients - such as a loss of the sense of smell or taste.

"We also found it in areas of the brain which control vital functions - such as breathing.

According to the NHS, the main symptoms of coronavirus are:

"Most people with coronavirus have at least one of these symptoms," says the health body.

If you have any of the main symptoms of coronavirus, you must get a test to check if you have coronavirus as soon as possible, according to public health advice.

You and anyone you live with should stay at home and not have visitors until you get your test result only leave your home to have a test.

Visit link:
Coronavirus may enter the brain through the nose - the neurological symptoms to look for - Express

Impact Of Covid-19 On Oncology & Neurology Disorder Drugs Market Is Slated To Grow Rapidly In The Forthcoming Years With Key Players ProStrakan,…

Posted on December 1, 2020 by Danzig

DataIntelo, a prominent market research firm, has published a detailed report on Global Oncology & Neurology Disorder Drugs Market. This market research report provides comprehensive and in-depth analysis on the market which can possibly help an enterprise to identify lucrative opportunities and assist them with fabricating creative business strategies. The market report provides information about the current market scenario regarding the global supply and demand, key market trends and opportunities in the market, and challenges and threats faced by the industry players.

The Oncology & Neurology Disorder Drugs market report talks about the competitive scenario among the industry players and imparts aspiring and emerging industry players with the future market insights in a detailed manner. This market report includes crucial data and figures which are structured out in a concise yet understandable manner. The research report covers the updates on the government regulations and policies which illustrates key opportunities and challenges of the market. DataIntelo has been monitoring the market since few years and collaborated with eminent players of the industry to give better insights on the market. It has conducted vigorous research and implied robust methodology to provide accurate predictions about the market.

You can buy the complete report on @ https://dataintelo.com/checkout/?reportId=44608

Impacts of Advancements and COVID-19 on the market.

Amidst the COVID-19, few segments of the market have witnessed a disruption due to the gap in supply and demand which has impacted the growth of the Oncology & Neurology Disorder Drugs market. Along with this, the latest advancements have changed the market dynamics of the market. This research report covers the wide-range analysis of the COVID-19 impact to the industry and gives out insights on the change in the market scenario due to the advancements.

Request A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=44608

Market Segmentation

Some of the major companies that are covered in the report.

ProStrakanPacira PharmaceuticalsAbbottGlaxoSmithKlineTranscept PharmaceuticalsArchimedes

Note: Additional companies

Based on the type, the market is segmented into

Product Type IProduct Type IIProduct Type III

Based on the application, the market is segregated into

Application IApplication IIApplication III

Based on the geographical location, the market is segregated into

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

DataIntelo provides yearly updates on the Oncology & Neurology Disorder Drugs market that assist the clients to stay ahead in the competitive space.

Why one should buy this Oncology & Neurology Disorder Drugs Report?

The market research report provides all valuable constituents of the market such as revenue growth, product pricing & analysis, growth potential, and guidelines to tackle the challenges in the market. The report covers all the crucial mergers & acquisitions, partnerships, and collaborations that created further created opportunities or in some cases, challenges for the industry players.

This report includes latest product news, advancements, and updates from the prominent player of the industry that has leveraged their position in the market. It also provides business strategies implemented by the key players and yardstick to arrive on informed business decisions. Moreover, it gives insights on the consumer behavior patterns that can help the enterprise to curate the business strategies accordingly.

DataIntelo bestows the clients with the specialized customized options related to the regional analysis, company analysis, and product analysis, among others.

Complete Table Content of the Market

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Oncology & Neurology Disorder Drugs Market Overview

Oncology & Neurology Disorder Drugs Supply Chain Analysis

Oncology & Neurology Disorder Drugs Pricing Analysis

Global Oncology & Neurology Disorder Drugs Market Analysis and Forecast by Type

Global Oncology & Neurology Disorder Drugs Market Analysis and Forecast by Application

Global Oncology & Neurology Disorder Drugs Market Analysis and Forecast by Sales Channel

Global Oncology & Neurology Disorder Drugs Market Analysis and Forecast by Region

North America Oncology & Neurology Disorder Drugs Market Analysis and Forecast

Latin America Oncology & Neurology Disorder Drugs Market Analysis and Forecast

Europe Oncology & Neurology Disorder Drugs Market Analysis and Forecast

Asia Pacific Oncology & Neurology Disorder Drugs Market Analysis and Forecast

Asia Pacific Oncology & Neurology Disorder Drugs Market Size and Volume Forecast by Application

Middle East & Africa Oncology & Neurology Disorder Drugs Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=44608

About the Company

DataIntelo is the largest aggregator of the market research report in the industry with more than 800 global clients. The company has extensively invested in the research analysts training and programs to keep the analyst tapped with the best industry standards and provide the clients with the&utmost experience. Our dedicated team has been collaborating with the industry experts to give out the precise data and figures related to the industry. It conducts primary research, secondary research, and consumer surveys to provide an in-depth analysis of the market. The market research firm has worked in several business verticals and has been successful to earn high credentials over the time.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review -…

Posted on November 13, 2020 by Danzig

This article was originally published here

Clin Neurol Neurosurg. 2020 Nov 1:106349. doi: 10.1016/j.clineuro.2020.106349. Online ahead of print.

ABSTRACT

BACKGROUND: Patients with chronic diseases likely develop severe 2019 coronavirus disease (COVID-19). However, little is known about the effects of COVID-19 on patients with neurological disorders. We conducted a systematic review to evaluate the severity of COVID-19 and its effect on neurological symptoms in patients with preexisting neurological disorder and COVID-19.

METHODS: We searched the MEDLINE (PubMed) and medRxiv databases for reports of patients with both preexisting neurological disorders and COVID-19. Studies reporting data on changes in the symptoms of preexisting neurological disorders and/or the severity of COVID-19 were included.

RESULTS: Twenty-six articles with 2278 patients with preexisting neurological disorder and COVID-19 were identified. Of 232 patients, 74 (31.9 %) showed exacerbation of preexisting neurological symptoms of dementia (55/92; 59.5 %), Parkinsons disease (10/17; 58.8 %), epilepsy (1/1; 100 %), and unspecified neurological disorders (8/106; 7.5 %). Of 2168 patients, 478 (22.0 %) showed severe COVID-19 course. These included patients with cerebrovascular disease (86/445; 19.3 %), dementia (70/316; 22.2 %), Parkinsons disease (25/214; 11.7 %), multiple sclerosis (28/71; 39.4 %), spinal cord injury (5/7; 71.4 %), epilepsy (10/98; 10.2 %) and unspecified neurological disorders (254/1011; 25 %).

CONCLUSIONS: Patients with preexisting neurological disorders and COVID-19 may develop exacerbation of neurological symptoms and severe COVID-19. Clinicians should be aware of the risk of symptom exacerbation and severe COVID-19 in patients with preexisting neurological disease and should focus on the prevention and early care of COVID-19.

PMID:33172719 | DOI:10.1016/j.clineuro.2020.106349

The rest is here:
Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review -...

Neurovascular Embolization Devices (Neurology) Market: Web Devices Emerge as Less-invasive Alternative for Neurovascular Embolization Treatment – The…

Posted on November 13, 2020 by Danzig

Transparency Market Research (TMR) has published a new report on the neurovascular embolization devices (neurology) market for the forecast period of 20192027. According to the report, the global neurovascular embolization devices (neurology) market was valued at ~US$ 1.2 Bn in 2018, and is projected to expand at a CAGR of ~3% from 2019 to 2027.

Neurovascular Embolization Devices (Neurology) Market: Overview

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73906

Rise in Prevalence of Stroke to Drive Neurovascular Embolization Devices (Neurology) Market

Embolization Coils Dominated Neurovascular Embolization Devices (Neurology) Market

Request for Analysis of COVID-19 Impact on of Neurovascular Embolization Devices (Neurology) Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73906

Hemorrhagic Stroke Solutions Held Leading Share of Neurovascular Embolization Devices (Neurology) Market

Brain Aneurysms Indication to Lead Neurovascular Embolization Devices (Neurology) Market

Hospitals End User to be Prominent

Buy Neurovascular Embolization Devices (Neurology) Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=73906&ltype=S

North America to Dominate Market; Asia Pacific to Offer Significant Growth Opportunities

Growth Strategies of Key Players

More Trending Reports by Transparency Market Research

Laboratory Equipment Services Market: https://www.biospace.com/article/laboratory-equipment-services-market-exclusive-study-report-on-the-current-scenario-of-industry/

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See the article here:
Neurovascular Embolization Devices (Neurology) Market: Web Devices Emerge as Less-invasive Alternative for Neurovascular Embolization Treatment - The...

Select Page ::